News View All News arrow-button

Oct 17, 2018

IFM Therapeutics, LLC Appoints Matthew Roden, Ph.D. as an Observer to the IFM Tre Board of Directors

IFM Therapeutics, LLC (IFM), a privately held biopharmaceutical company focused on developing therapies that modulate novel targets in the innate immune system, today announced that Matthew Roden, Ph.D., Head of Strategic Corporate Development and Global Business Development Assessment at Bristol-Myers Squibb (BMS), has been appointed as a Board Observer to the IFM Tre Board of Directors. IFM Tre is a recently established subsidiary that is developing a suite of different NLRP3 antagonists that can potentially block the inflammatory responses underlying a variety of serious diseases.

At BMS, Roden is responsible for overseeing the Mergers & Acquisition team accountable for acquisitions, structured transactions, strategic equity investing, and divestitures. He also leads Global Search and Evaluation activities and sits on the Research and Development Leadership Team. Prior to joining BMS, he was most recently the Head of the Biotechnology Equity Research Team at UBS, and was previously a senior biotech equity analyst at Bank of America Merrill Lynch and J.P. Morgan.

“Matthew is a very talented, accomplished analyst and advisor within the biopharmaceutical industry and we are thrilled to welcome him to our Board of Directors,” said Gary D. Glick, Ph.D., co-founder and Chief Executive Officer of IFM. “His experience will be invaluable as IFM Tre works to propel its NLRP3 antagonist programs toward the clinic, with the goal of harnessing the untapped potential of the NLRP3 inflammasome target for a wide range of serious inflammation-driven disorders.”

Roden holds a Ph.D. in Microbiology and Immunology from the Albert Einstein College of Medicine, and earlier was a pre-doctoral clinical research fellow in immuno-oncology at the National Cancer Institute in Bethesda, Maryland. In addition to his Board Observer role with IFM Tre, he serves on the Board of Trustees of BioNJ and the Governor’s Innovation Evergreen Fund Roundtable, and is an Advisory Committee Board member for the BIO conferences.

About IFM Tre

IFM Tre, a subsidiary of IFM Therapeutics, LLC, is a biopharmaceutical company developing a suite of small-molecule antagonists targeting inappropriate inflammatory responses of the innate immune system via the NLRP3 pathway, which is believed to underlie a variety of serious diseases. The Company is developing chemically distinct systemic, gut-directed and CNS-penetrant drug candidates to address a breadth of indications triggered by NLRP3, including metabolic, fibrotic, autoimmune, autoinflammatory, and neurodegenerative diseases.

About IFM Therapeutics, LLC

IFM Therapeutics, LLC is a privately held biopharmaceutical company based in Boston, Massachusetts. The company was founded by an international group of preeminent scientists and physicians who have spent decades understanding innate immunity and the role it plays in regulating the immune system. IFM’s team has discovered and developed small molecules that modulate novel targets in the innate immune system as next-generation therapies for cancer, auto-immunity, and inflammatory disorders. For more information, please visit    

Media Contact:
Andrew Bailey 
P: (+1) 202-587-2521

Investor Contact:
Stern Investor Relations, Inc.
Hannah Deresiewicz
P: (+1) 212-362-1200





Media Contact

Andrew Bailey
Spectrum Science Communications